CAS: 3721-95-7; Cyclobutanecarboxylic Acid

相似化合物

14924-53-9 4415-82-1 4426-11-3

上下游产品

环丁烷甲酸乙酯 Ethyl Cyclobutylcarboxylate 14924-53-9
环丁基甲醛 Cyclobutylaldehyde 2987-17-9

环丁基甲酰氯置于全氟碘代丁烷,Sodium Hydrosulfide Monohydrate,二甲基亚砜体系中,用 甲醇 用作溶剂,化学反应 29.0H,反应生成环丁基甲酸
参考文献:通过可见光促进的原子取代过程将硫代酸转化为羧酸
标题:通过可见光促进的原子取代过程将硫代酸转化为羧酸
摘要:已经开发了一种可见光促进的原子取代反应,用于以二甲亚砜 (Dmso) 作为氧源将硫代酸转化为羧酸,以超过 90% 的收率提供各种烷基和芳基羧酸.通过硫代酸和 Dmso 之间形成的氢键加合物的光化学反应,原子取代过程顺利进行.提出了涉及 Dmso 的质子耦合电子转移 (Pcet) 以及同时产生硫基和羟基自由基是实现转化的关键步骤.
Doi:10.1021/acs.Orglett.2C00481

专利信息

专利号:US-7423169-B2
优先权日:2001-06-11
标 题:Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
发明人：RAILLARD STEPHEN P; ZHOU CINDY X; YAO FENMEI; MANTHATI SURESH KUMAR; XIANG JIA-NING; GALLOP MARK A
权利人:XENOPORT INC
摘要:The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.

专利号:US-10040752-B2
优先权日:2015-08-24
标 题 :Synthesis of levomethadone hydrochloride or dextromethadone hydrochloride and methods for use thereof
发明人：MKRTCHYAN GNEL; YAO QINGWEI
权利人:CODY LABORATORIES INC
摘要:Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are provided comprising administering a composition comprising an effective amount of levomethadone hydrochloride having not more than 10 ppm dextromethadone.

专利号:US-2013338369-A1
优先权日:2011-03-07
标 题 :Process for the Synthesis of Aminobiphenylene
发明人：HEINRICH MARKUS; PRATSCH GERALD
权利人:HEINRICH MARKUS; PRATSCH GERALD; BASF SE
摘要:The present invention relates to a process for the synthesis of 2-aminobiphenylene and derivatives thereof by reacting a benzene diazonium salt with an aniline compound under basic reaction conditions.

专利号:US-11401273-B2
优先权日:2018-11-20
标题:Asymmetric synthesis of Azaspiro compounds
发明人：LELETI RAJENDER REDDY; WAMAN YOGESH; KALLURE PRIYA; BEGUM ZUBEDA; DIVYA THUMBAN; NALIVELA KUMARA SWAMY; VIJAY SAURABH; PARIKH PARANJAY; KOTTURI SHARADSRIKAR; PATEL CHIRAG; NAYAK KRISHNA; BAHAROONI KASIMRAZA; ZALAVADIYA VINKAL
权利人:PIRAMAL PHARMA LTD
摘要:The present invention relates to an improved asymmetric synthesis of azaspiro or diazaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the formation of intermediate compounds 4, (4A) or (4N) respectively. The process comprises an unusual substrate specific highly diastereoselective as well as enantio-enriched 1-substituted 2-azaspiro[3.3]heptane or 1-substituted 2-diazaspiro[3.3]heptane compounds with high diastereoselectivity by addition of a cyclobutane carboxylate anion to a Davis-Ellman's imine, followed by reduction and cyclisation resulting in the selective formation of azaspiro or diazaspiro intermediate compound 4, (4A) or (4N); which on subsequently removing the sulfinyl group provides corresponding azaspiro or diazaspiro compound 5, (5A) or (5N) respectively.

专利号:US-4400550-A
优先权日:1982-02-12
标题 :Synthesis of the navel orange worm pheromone (Z,Z)-11,13-hexadecadienal
发明人：BISHOP CLYDE E; MORROW GARY W
权利人:ALBANY INT CORP
摘要:A process for the synthesis of (Z,Z)-11-13-hexadecadienal is disclosed, starting with undecylenic alcohol.

专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.